<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00604331</url>
  </required_header>
  <id_info>
    <org_study_id>PYR-2008-01</org_study_id>
    <secondary_id>12/10/00</secondary_id>
    <nct_id>NCT00604331</nct_id>
  </id_info>
  <brief_title>Effects of Pyruvate in Patients With Cardiogenic Shock and Intra-aortic Balloon Counterpulsation</brief_title>
  <official_title>Effects of Pyruvate in Patients With Cardiogenic Shock and Intra-aortic Balloon Counterpulsation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herzzentrum Goettingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herzzentrum Goettingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pyruvate is an intermediate of energy metabolism and was shown to possess pronounced positive
      inotropic effects in vitro and in vivo without altering myocardial oxygen consumption.
      Moreover, it was shown that the effects of beta-adrenergic stimulation were potentiated.
      Thus, it might be possible to save catecholamines in patients with severe heart failure or
      cardiogenic shock. This study was designed to test the hemodynamic effects of pyruvate
      administered into a coronary artery in addition to intra-aortic balloon pump counterpulsation
      in patients with severe heart failure or in patients with acute myocardial infarction and
      cardiogenic shock after having performed percutaneous coronary intervention. A pronounced
      improvement in hemodynamics is expected to occur.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac Output</measure>
    <time_frame>60 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac Index</measure>
    <time_frame>60 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial Pressure</measure>
    <time_frame>60 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary capillary wedge pressure</measure>
    <time_frame>60 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary artery pressure</measure>
    <time_frame>60 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>systemic vascular resistance</measure>
    <time_frame>60 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulmonary vascular resistance</measure>
    <time_frame>60 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate</measure>
    <time_frame>60 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stroke volume</measure>
    <time_frame>60 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>catecholamine need</measure>
    <time_frame>60 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>60 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Shock, Cardiogenic</condition>
  <condition>Heart Failure</condition>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pyruvate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyruvate</intervention_name>
    <description>sodium pyruvate 300 mmol/L, 360 mL/h i.c. over 30 minutes.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized patients male/female

          -  Age: 18 - 85 years

          -  Weight: 45 - 110 kg

          -  Height 150 - 195 cm

          -  Clinically signs of heart failure (NYHA III-IV) refractary to therapy or cardiogenic
             shock in acute myocardial infarction

          -  written informed consent or witnessed verbal consent or presumed will (compassionate
             use)

        Exclusion Criteria:

          -  Malignoma

          -  Clinically significant cardiac valve stenosis

          -  Participation in another clinical trial with relevant or probable drug-interactions

          -  Pregnancy or lactation

          -  Addiction

          -  Poor compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerd Hasenfuss, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzzentrum Goettingen, Cardiology and Pneumology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herzzentrum Goettingen, Cardiology and Pneumology</name>
      <address>
        <city>Goettingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.herzzentrum-goettingen.de/</url>
    <description>Heart Center of Goettingen</description>
  </link>
  <reference>
    <citation>Hermann HP, Pieske B, Schwarzmüller E, Keul J, Just H, Hasenfuss G. Haemodynamic effects of intracoronary pyruvate in patients with congestive heart failure: an open study. Lancet. 1999 Apr 17;353(9161):1321-3.</citation>
    <PMID>10218531</PMID>
  </reference>
  <results_reference>
    <citation>Schillinger W, Hünlich M, Sossalla S, Hermann HP, Hasenfuss G. Intracoronary pyruvate in cardiogenic shock as an adjunctive therapy to catecholamines and intra-aortic balloon pump shows beneficial effects on hemodynamics. Clin Res Cardiol. 2011 May;100(5):433-8. doi: 10.1007/s00392-010-0261-4. Epub 2010 Dec 4.</citation>
    <PMID>21132310</PMID>
  </results_reference>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2008</study_first_submitted>
  <study_first_submitted_qc>January 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2008</study_first_posted>
  <last_update_submitted>December 7, 2010</last_update_submitted>
  <last_update_submitted_qc>December 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Gerd Hasenfuss/Professor Dr. med.</name_title>
    <organization>Cardiology and Pneumology</organization>
  </responsible_party>
  <keyword>Pyruvic Acid</keyword>
  <keyword>Shock, Cardiogenic</keyword>
  <keyword>Catecholamines</keyword>
  <keyword>Intra-Aortic Balloon Pumping</keyword>
  <keyword>Cardiac Output</keyword>
  <keyword>Cardiac Index</keyword>
  <keyword>Cardiac Function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Cardiogenic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

